WEST BRIDGEWATER, Mass., Dec. 5 -- Boston Biomedica, Inc. (Nasdaq: BBII) today announced that Richard T. Schumacher, Founder, CEO and Chairman of Boston Biomedica was interviewed by Dave Anthony of Boston Business Journal Radio AM Edition (1060AM). Mr. Schumacher discussed the Company's recent release of its first West Nile Virus product, its patented Pressure Cycling Technology and other aspects of current business.
To hear the full interview, click on the following link: http://www.business1060.com/send_friend/audio.asp?show=bbj_am
Boston Biomedica, Inc. provides products and services to the diagnostics and life sciences industries to evaluate, monitor, and ensure the quality of infectious disease test results, to improve the preparation of specimens for genomic/proteomic testing, and to safely store and retrieve rare and valuable biological specimens. We also manufacture biological reagents used in test kits and provide a broad range of routine and esoteric research services to governments and industry. BBI operates in three states, and conducts research in new applications for our patented Pressure Cycling Technology (PCT). In 2000, we launched Panacos Pharmaceuticals, and the Company maintains a significant passive investment in this novel antiviral drug development company.
Statements contained in this news release that state the Company's or management's intentions, hopes, beliefs, expectations or predictions of the future are "forward-looking'' statements. It is important to note that the Company's actual results could differ materially from those projected in such forward-looking statements. Factors that could cause actual results to differ from those projected include the possibility that Boston Biomedica may not be successful in commercializing its first West Nile Virus QC product, that the Company may not be successful in developing additional WNV products, or that these products may not be needed by developers or users of WNV tests. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company's SEC filings, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2001 and the Company's Quarterly Reports on Form 10-Q for the three months ended March 31, June 30, and September 30, 2002. Copies of these documents may be obtained by contacting the Company or the SEC.
Visit us at our website http://www.bbii.com Please email us at IR@bbii.com if you prefer to receive future announcements electronically
| Investor Contacts: | Media Contact: |
| Richard T. Schumacher, CEO & Chairman Kevin W. Quinlan, President & COO Boston Biomedica, Inc. 508-580-1900 (T) |
Liz Falcone Schneider & Associates 617-536-3300 (T) |
SOURCE Boston Biomedica, Inc.
